Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-30T19:15:17.205Z Has data issue: false hasContentIssue false
  • English
  • Français

Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

Published online by Cambridge University Press:  05 August 2019

Rachel Koo ,
Jennifer Lo  and
Matthew J. Bock Open the ORCID record for Matthew J. Bock [Opens in a new window]
Rachel Koo
Affiliation:
Department of Pediatrics, Loma Linda University Children’s Health, Loma Linda, CA, USA
Jennifer Lo
Affiliation:
Division of Pediatric Cardiology, Loma Linda University Children’s Health, Loma Linda, CA, USA
Matthew J. Bock*
Affiliation:
Division of Pediatric Cardiology, Loma Linda University Children’s Health, Loma Linda, CA, USA
*
Author for correspondence: Matthew J Bock, MD, Loma Linda University Medical Center, 11234 Anderson St., MC-4434, Loma Linda, CA 92354, USA. Tel: 909-558-8083; Fax: 888-365-2421; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

Keywords

Selexipaginfantprostacyclinpulmonary hypertensionpaediatric
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 6 , June 2019 , pp. 849 - 851
Check for updates
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ferdman, DJ, Rosenzweig, EB, Zuckerman, WA, Krishnan, U. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy. Pediatrics 2014; 134: e274–e278.CrossRefGoogle ScholarPubMed
Levy, M, Del Cerro, MJ, Nadaud, S, et al. Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol 2018; 264: 153–157.CrossRefGoogle ScholarPubMed
McIntyre, CM, Hanna, BD, Rintoul, N, Ramsey, EZ. Safety of epoprostenol and treprostinil in children less than 12 months of age. Pulm Circ 2013; 3: 862–869.CrossRefGoogle ScholarPubMed
Sitbon, O, Channick, R, Chin, KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.CrossRefGoogle ScholarPubMed
Geerdink, LM, Bertram, H, Hansmann, G. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulm Circ 2017; 7: 551–554.CrossRefGoogle ScholarPubMed
Gallotti, R, Drogalis-Kim, DE, Satou, G, Alejos, J. Single-center experience using selexipag in a pediatric population. Pediatr Cardiol 2017; 38: 1405–1409.CrossRefGoogle Scholar
European Medicines Agency Assessment Report. Uptravi. (2016). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003774/WC500207175.pdf Google Scholar
Supplementary material: Image

Koo et al. supplementary material

Koo et al. supplementary material 1

Download Koo et al. supplementary material(Image)
Image 8.5 MB
Supplementary material: Image

Koo et al. supplementary material

Koo et al. supplementary material 2

Download Koo et al. supplementary material(Image)
Image 12.8 MB